Morten Graugaard Døssing

Morten joined Novo Seeds in 2016 as Investment Director. Prior to joining Novo, Morten was Director of Corporate Development at H. Lundbeck A/S where he was involved in M&A (including leading the acquisition orphan neurology company Chelsea Therapeutics), corporate strategy, BD&L, portfolio management and equity investments. He also serves on the Board of Hoba Therapeutics, Merozyne Therapeutics and NMD Pharma.